Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
D Nolan - Drug safety, 2005 - Springer
Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic
complications, have emerged as important long-term toxicities associated with antiretroviral …
complications, have emerged as important long-term toxicities associated with antiretroviral …
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
D Nolan - Drug Safety, 2005 - europepmc.org
Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic
complications, have emerged as important long-term toxicities associated with antiretroviral …
complications, have emerged as important long-term toxicities associated with antiretroviral …
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
D Nolan - Drug safety, 2005 - pubmed.ncbi.nlm.nih.gov
Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic
complications, have emerged as important long-term toxicities associated with antiretroviral …
complications, have emerged as important long-term toxicities associated with antiretroviral …
[PDF][PDF] Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
D Nolan - Drug Safety, 2005 - core.ac.uk
Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic
complications, have emerged as important long-term toxicities associated with antiretroviral …
complications, have emerged as important long-term toxicities associated with antiretroviral …
Do Non-Nucleoside Reverse Transcriptase Inhibitors Contribute to Lipodystrophy?
D Nolan - Drug Safety, 2005 - infona.pl
Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic
complications, have emerged as important long-term toxicities associated with antiretroviral …
complications, have emerged as important long-term toxicities associated with antiretroviral …
[引用][C] Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
D NOLAN - Drug safety, 2005 - pascal-francis.inist.fr
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy? CNRS Inist
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
[PDF][PDF] Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
D Nolan - Drug Safety, 2005 - researchportal.murdoch.edu.au
Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic
complications, have emerged as important long-term toxicities associated with antiretroviral …
complications, have emerged as important long-term toxicities associated with antiretroviral …
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
D Nolan - Drug Safety, 2005 - go.gale.com
Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic
complications, have emerged as important long-term toxicities associated with antiretroviral …
complications, have emerged as important long-term toxicities associated with antiretroviral …
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
D Nolan - Drug Safety, 2005 - researchportal.murdoch.edu.au
Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic
complications, have emerged as important long-term toxicities associated with antiretroviral …
complications, have emerged as important long-term toxicities associated with antiretroviral …